Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education

Abstract

Background. Inflammatory bowel disease (IBD) affects patients in their young reproductive years. Women with IBD require maintenance therapies during pregnancy and breastfeeding. However, physician management of IBD during pregnancy and breastfeeding has not been well characterized. Objective. To characterize physician perceptions and management of IBD during pregnancy and breastfeeding. Methods. A cross-sectional survey of Canadian physicians who are involved in the care of women with IBD was conducted. The survey included multiple-choice and Likert scale questions about perceptions and practice patterns regarding the management of IBD during pregnancy and breastfeeding. Results. 183 practicing physicians completed the questionnaire: 97/183 (53.0%) gastroenterologists; 75/183 (41.0%) general practitioners; and 11/183 (6.0%) other physicians. Almost half (87/183, 47.5%) of the physicians felt comfortable managing pregnant IBD patients. For specified IBD medications, proportions of physicians who indicated they would continue them during pregnancy were as follows: sulfasalazine, 47.4%; oral mesalamine, 67.0%; topical mesalamine, 70.3%; oral prednisone, 68.0%; topical prednisone, 78.0%; oral budesonide, 61.6%; topical budesonide, 75.0%; ciprofloxacin, 15.3%; metronidazole, 31.4%; azathioprine, 57.1%; methotrexate, 2.8%; infliximab, 55.6%; adalimumab, 78.1%. Similar proportions of physicians would continue these medications during breastfeeding. A higher proportion of gastroenterologists than nongastroenterologists indicated appropriate use of these IBD medications during pregnancy and breastfeeding. Conclusions. Physician management of IBD during pregnancy and breastfeeding varies widely. Relative to other physicians, responses of gastroenterologists more frequently reflected best practices pertaining to medications for control of IBD during pregnancy and breastfeeding. There is a need for further education regarding the management of IBD during pregnancy and breastfeeding.

Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience

“…75 Survey data showed that approximately 80% of the physicians do not object to the administration of adalimumab during pregnancy and lactation (indication was not restricted to psoriasis), compared with only 56% for infliximab and 3% for methotrexate. 76 However, the Australasian Psoriasis Collaboration generally recommends conventional drugs for pregnant or breastfeeding patients, instead of using newer alternatives with less foetal safety data. 77 Adalimumab has been approved by the European Medicines Agency as a first-line treatment for severe chronic plaque psoriasis in children (⩾4 years old) and adolescents.…”

The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn

“…Due to the strong evidence that active IBD increases the likelihood of adverse pregnancy outcomes, therapeutic interventions during pregnancy are still considered as the primary option for protecting both mother and fetus. 10,11 One of the major concerns for parents with IBD is the possible impact of IBD and its medications on the growing fetus and breastfed infant. A large body of evidence supports the protective role of breastfeeding against IBD by influencing offspring gut microbiome establishment and development of the innate mucosal immunity.…”

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database

“…19 Further supporting this notion, a survey conducted among 183 Canadian physicians reported that a substantial number would feel uncomfortable recommending the continuation of TNF-α therapy during pregnancy (44% for IFX, 22% for ADA). 20 …”